Fight fire with fire: the need for a vaccine based on intrinsic disorder and structural flexibility

Abstract

The absence of advancement in finding efficient vaccines for several human viruses, such as hepatitis C virus (HCV), human immunodeficiency virus type 1 (HIV-1), and herpes simplex viruses (HSVs) despite 30, 40, and even 60 years of research, respectively, is unnerving. Among objective reasons for such failure are the highly glycosylated nature of proteins used as primary vaccine targets against these viruses and the presence of neotopes and cryptotopes, as well as high mutation rates of the RNA viruses HCV and HIV-1 and the capability to establish latency by HSVs. However, the lack of success in utilization of the structure-based reverse vaccinology for these viruses is likely to be related to the presence of highly flexible and intrinsically disordered regions in human antibodies (Abs) and the major immunogens of HIV-1, HCV, and HSVs, their surface glycoproteins. This clearly calls for moving from the rational structure-based vaccinology to the unstructural vaccinology based on the utilization of tools designed for the analysis of disordered and flexible proteins, while looking at intrinsically disordered viral antigens and their interactions with intrinsically disordered/flexible Abs.

Keywords

Reverse vaccinology / intrinsically disordered protein / antibody / antigen / structural flexibility

References

[1] Masignani V, Rappuoli R, Pizza M. Reverse vaccinology: a genome-based approach for vaccine development. Expert Opin Biol Ther. 2002; 2: 895-905.

[2] Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001; 19: 2688-91.

[3] Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002; 2: 706-13.

[4] Rinaudo CD, Telford JL, Rappuoli R, Seib KL. Vaccinology in the genome era. J Clin Invest. 2009; 119: 2515-25.

[5] Burton DR. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci U S A. 2010; 107: 17859-60.

[6] Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJM, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015; 6: 8143.

[7] Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017; 114: E7348-57.

[8] Shriver Z, Trevejo JM, Sasisekharan R. Antibody-based strategies to prevent and treat influenza. Front Immunol. 2015; 6: 315.

[9] Robinson LN, Tharakaraman K, Rowley KJ, Costa VV, Chan KR, Wong YH, et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell. 2015; 162: 493-504.

[10] Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013; 3: 521-30.

[11] Azoitei ML, Ban YEA, Julien JP, Bryson S, Schroeter A, Kalyuzhniy O, et al. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J Mol Biol. 2012; 415: 175-92.

[12] Azoitei ML, Correia BE, Ban YEA, Carrico C, Kalyuzhniy O, Chen L, et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science. 2011; 334: 373-6.

[13] Pack SM, Peters PJ. SARS-CoV-2-specific vaccine candidates; the contribution of structural vaccinology. Vaccines (Basel). 2022; 10: 236.

[14] Rappuoli R, De Gregorio E, Del Giudice G, Phogat S, Pecetta S, Pizza M, et al. Vaccinology in the post-COVID-19 era. Proc Natl Acad Sci U S A. 2021; 118: e2020368118.

[15] Edmundson AB, Ely KR, Herron JN, Cheson BD. The binding of opioid peptides to the Mcg light chain dimer: flexible keys and adjustable locks. Mol Immunol. 1987; 24: 915-35.

[16] Luciw PA. Human immunodeficiency viruses and their replication. In: Fields BN, Knippe DM, Howley PM, editors. Field virology. Philadelphia: Lippincott-Raven; 1996. pp. 1881-952.

[17] Li G, Piampongsant S, Faria NR, Voet A, Pineda-Peña AC, Khouri R, et al. An integrated map of HIV genome-wide variation from a population perspective. Retrovirology. 2015; 12: 18.

[18] Behrens AJ, Crispin M. Structural principles controlling HIV envelope glycosylation. Curr Opin Struct Biol. 2017; 44: 125-33.

[19] Schiller J, Chackerian B. Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog. 2014; 10: e1004254.

[20] Global HIV & AIDS statistics - fact sheet [Internet]. Switzerland: UNAIDS; c2022 [cited 2022 May 30]. Available from: https://www.unaids.org/en/resources/fact-sheet

[21] Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. ; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016; 375: 830-9.

[22] Barré-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013; 11: 877-83.

[23] Mu Z, Haynes BF, Cain DW. HIV mRNA vaccines-progress and future paths. Vaccines (Basel). 2021; 9: 134.

[24] Trovato M, D’Apice L, Prisco A, De Berardinis P. HIV vaccination: a roadmap among advancements and concerns. Int J Mol Sci. 2018; 19: 1241.

[25] Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine. 2013; 31: 3502-18.

[26] Ward B. Antiviral vaccines. In: Acheson NH, editor. Fundamentals of molecular virology. Hoboken: Wiley; 2007. pp. 428-55.

[27] Goh GKM, Dunker AK, Foster JA, Uversky VN. HIV vaccine mystery and viral shell disorder. Biomolecules. 2019; 9: 178.

[28] Goh GKM. Viral shapeshifters: strange behavoirs of HIV and other viruses. Singapore: Simplicity Research Institute; 2017.

[29] Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007; 445: 732-7.

[30] West AP Jr, Galimidi RP, Foglesong CP, Gnanapragasam PNP, Huey-Tubman KE, Klein JS, et al. Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol. 2009; 83: 98-104.

[31] Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 2007; 15: 211-8.

[32] Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ . Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem. 1990; 265: 10373-82.

[33] Chakraborty S, Berndsen ZT, Hengartner NW, Korber BT, Ward AB, Gnanakaran S. Quantification of the resilience and vulnerability of HIV-1 native glycan shield at atomistic detail. iScience. 2020; 23: 101836.

[34] LeBlanc EV, Kim Y, Capicciotti CJ, Colpitts CC. Hepatitis C virus glycan-dependent interactions and the potential for novel preventative strategies. Pathogens. 2021; 10: 685.

[35] Khattar SK, Samal S, LaBranche CC, Montefiori DC, Collins PL, Samal SK. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PLoS One. 2013; 8: e78521. Retraction in: Khattar SK, Samal S, LaBranche CC, Montefiori DC, Collins PL, Samal SK. PLoS One. 2020;15:e0244046. Erratum in: PLoS One. 2014;9.

[36] Van Regenmortel MHV. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol. 2012; 3: 194.

[37] Wu X, Changela A, O’Dell S, Schmidt SD, Pancera M, Yang Y, et al. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J Virol. 2011; 85: 4578- 85.

[38] Pantophlet R. Antibody epitope exposure and neutralization of HIV-1. Curr Pharm Des. 2010; 16: 3729-43.

[39] Zolla-Pazner S, Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol. 2010; 10: 527-35.

[40] Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol. 2010; 84: 8098-110.

[41] Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, et al. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIV_SF162P4 . J Virol. 2010; 84: 3443-53.

[42] Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009; 326: 285-9.

[43] Broder CC, Earl PL, Long D, Abedon ST, Moss B, Doms RW. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A. 1994; 91: 11699-703.

[44] Kimura T, Wang XH, Williams C, Zolla-Pazner S, Gorny MK. Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins. Hum Antibodies. 2009; 18: 35-40.

[45] Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005; 79: 5232-7.

[46] Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, et al. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol. 2011; 85: 2524-35.

[47] Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol. 2007; 81: 1424-32.

[48] Pejaver V, Hsu WL, Xin F, Dunker AK, Uversky VN, Radivojac P. The structural and functional signatures of proteins that undergo multiple events of post-translational modification. Protein Sci. 2014; 23: 1077-93.

[49] McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011; 480: 336-43.

[50] Ehrhard B, Misselwitz R, Welfle K, Hausdorf G, Glaser RW, Schneider-Mergener J, et al. Chemical modification of recombinant HIV-1 capsid protein p24 leads to the release of a hidden epitope prior to changes of the overall folding of the protein. Biochemistry. 1996; 35: 9097-105.

[51] Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol. 1993; 67: 3978-88.

[52] Van Regenmortel MHV. Structure of viral B-cell epitopes. Res Microbiol. 1990; 141: 747-56.

[53] Rieder FJJ, Biebl J, Kastner MT, Schneider M, Jungbauer C, Redlberger-Fritz M, et al. Microbial cryptotopes are prominent targets of B-cell immunity. Sci Rep. 2016; 6: 31657.

[54] Stiasny K, Kiermayr S, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol. 2006; 80: 9557-68.

[55] Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology. 2012; 422: 174-84.

[56] Ekiert DC, Bhabha G, Elsliger MA, Friesen RHE, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324: 246-51.

[57] Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen L, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009; 16: 265-73.

[58] Meyerhans A, Cheynier R, Albert J, Seth M, Kwok S, Sninsky J, et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations . Cell. 1989; 58: 901-10.

[59] Peng K, Radivojac P, Vucetic S, Dunker AK, Obradovic Z. Length-dependent prediction of protein intrinsic disorder. BMC Bioinformatics. 2006; 7: 208.

[60] Romero P, Obradovic Z, Li X, Garner EC, Brown CJ, Dunker AK. Sequence complexity of disordered protein. Proteins. 2001; 42: 38-48.

[61] Xue B, Dunbrack RL, Williams RW, Dunker AK, Uversky VN. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta. 2010; 1804: 996-1010.

[62] Peng K, Vucetic S, Radivojac P, Brown CJ, Dunker AK, Obradovic Z. Optimizing long intrinsic disorder predictors with protein evolutionary information. J Bioinform Comput Biol. 2005; 3: 35-60.

[63] Dosztányi Z, Csizmok V, Tompa P, Simon I. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics. 2005; 21: 3433-4.

[64] Dosztányi Z, Csizmók V, Tompa P, Simon I. The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins. J Mol Biol. 2005; 347: 827-39.

[65] Mészáros B, Erdős G, Dosztányi Z. IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding. Nucleic Acids Res. 2018; 46: W329-37.

[66] Uversky VN. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder. Arch Virol. 2021; 166: 1283-96.

[67] Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011; 364: 2429-38.

[68] Ray SC, Thomas DL. Chapter 154: Hepatitis C. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone; 2009. pp. 2157-86.

[69] Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol. 2007; 13: 2406-15.

[70] Hepatitis C [Internet]. Switzerland: WHO; c2022 [cited 2022 May 19]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c

[71] Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016; 22: 833-8.

[72] Global Burden of Disease Study 2013 Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386: 743-800.

[73] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2095-128. Erratum in: Lancet. 2013;381:628.

[74] Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59: 318-27.

[75] Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, et al. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018; 8: 12266.

[76] The Lancet Gastroenterology & Hepatology. The hunt for a vaccine for hepatitis C virus continues. Lancet Gastroenterol Hepatol. 2021; 6: 253.

[77] Kong L, Kadam RU, Giang E, Ruwona TB, Nieusma T, Culhane JC, et al. Structure of hepatitis C virus envelope glycoprotein E1 antigenic site 314-324 in complex with antibody IGH526. J Mol Biol. 2015; 427: 2617-28.

[78] McGeoch DJ, Rixon FJ, Davison AJ. Topics in herpesvirus genomics and evolution. Virus Res. 2006; 117: 90-104.

[79] Krishnan R, Stuart PM. Developments in vaccination for herpes simplex virus. Front Microbiol. 2021; 12: 798927.

[80] James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020; 98: 315-29.

[81] Stanfield B, Kousoulas KG. Herpes simplex vaccines: prospects of live-attenuated HSV vaccines to combat genital and ocular infections. Curr Clin Microbiol Rep. 2015; 2: 125-36.

[82] Wijesinghe VN, Farouk IA, Zabidi NZ, Puniyamurti A, Choo WS, Lal SK. Current vaccine approaches and emerging strategies against herpes simplex virus (HSV). Expert Rev Vaccines. 2021; 20: 1077-96.

[83] Sandgren KJ, Truong NR, Smith JB, Bertram K, Cunningham AL. Vaccines for herpes simplex: recent progress driven by viral and adjuvant immunology. Methods Mol Biol. 2020; 2060: 31-56.

[84] Turner A, Bruun B, Minson T, Browne H. Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. J Virol. 1998; 72: 873-5.

[85] Arii J, Kawaguchi Y. The role of HSV glycoproteins in mediating cell entry. Adv Exp Med Biol. 2018; 1045: 3-21.

[86] Jambunathan N, Chowdhury S, Subramanian R, Chouljenko VN, Walker JD, Kousoulas KG. Site-specific proteolytic cleavage of the amino terminus of herpes simplex virus glycoprotein K on virion particles inhibits virus entry. J Virol. 2011; 85: 12910-8.

[87] Farnsworth A, Johnson DC. Herpes simplex virus gE/gI must accumulate in the trans-Golgi network at early times and then redistribute to cell junctions to promote cell-cell spread . J Virol. 2006; 80: 3167-79.

[88] Görander S, Harandi AM, Lindqvist M, Bergström T, Liljeqvist JÅǒ. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease. J Virol. 2012; 86: 7544-53.

[89] Liu Y, Guan X, Li C, Ni F, Luo S, Wang J, et al. HSV-2 glycoprotein J promotes viral protein expression and virus spread. Virology. 2018; 525: 83-95.

[90] Striebinger H, Funk C, Raschbichler V, Bailer SM. Subcellular trafficking and functional relationship of the HSV-1 glycoproteins N and M. Viruses. 2016; 8: 83.

[91] El Kasmi I, Lippé R. Herpes simplex virus 1 gN partners with gM to modulate the viral fusion machinery. J Virol. 2015; 89: 2313-23.

[92] Dorosti H, Eskandari S, Zarei M, Nezafat N, Ghasemi Y. Design of a multi-epitope protein vaccine against herpes simplex virus, human papillomavirus and Chlamydia trachomatis as the main causes of sexually transmitted diseases . Infect Genet Evol. 2021; 96: 105136.

[93] Sarkar B, Ullah MA. Designing novel subunit vaccines against herpes simplex virus-1 using reverse vaccinology approach. BioRxiv 901678 [Preprint]. 2020 [cited 2022, May 25]. Available from: https://doi.org/10.1101/2020.01.10.901678

[94] Sarkar B, Ullah MA, Araf Y, Das S, Rahman MH, Moin AT. Designing novel epitope-based polyvalent vaccines against herpes simplex virus-1 and 2 exploiting the immunoinformatics approach. J Biomol Struct Dyn. 2021; 39: 6585-605.

[95] Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Morris GM, Rudd PM, et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science. 2001; 293: 1155-9.

[96] Goldsby RA, Kindt TJ, Osborne BA, Kuby J. Antigens. In: Goldsby RA, Osborne BA, Kuby J, Kindt TJ, Marcus DA, Punt J, editors. Kuby Immunology. New York: W. H. Freeman; 2007. pp. 57-75.

[97] Kunert R, Rüker F, Katinger H. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res Hum Retroviruses. 1998; 14: 1115-28.

[98] Sanna PP, Williamson RA, De Logu A, Bloom FE, Burton DR. Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries. Proc Natl Acad Sci U S A. 1995; 92: 6439-43.

[99] Barbas CF III, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, et al. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol. 1993; 230: 812-23.

[100] Smith TJ, Chase ES, Schmidt TJ, Olson NH, Baker TS. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon. Nature. 1996; 383: 350-4.

[101] Regep C, Georges G, Shi J, Popovic B, Deane CM. The H3 loop of antibodies shows unique structural characteristics. Proteins. 2017; 85: 1311-8.

[102] Stanfield RL, Berndsen ZT, Huang R, Sok D, Warner G, Torres JL, et al. Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. Sci Adv. 2020; 6: eaba0468.

[103] Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1994; 10: 1651-8.

[104] Zhou T, Xu K. Structural features of broadly neutralizing antibodies and rational design of vaccine. Adv Exp Med Biol. 2018; 1075: 73-95.

[105] Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol. 2013; 20: 796-803.

[106] Burke V, Williams C, Sukumaran M, Kim SS, Li H, Wang XH, et al. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure. 2009; 17: 1538-46.

[107] Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, et al. Structure of a V3-containing HIV-1 gp120 core. Science. 2005; 310: 1025-8.

[108] Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure. 2004; 12: 193-204.

[109] Iakoucheva LM, Radivojac P, Brown CJ, O’Connor TR, Sikes JG, Obradovic Z, et al. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res. 2004; 32: 1037-49.

[110] Van Regenmortel MHV. Design in biology and rational design in vaccinology: a conceptual analysis. Methods. 2021; 195: 120-7.

[111] Van Regenmortel MHV. What does it mean to develop an HIV vaccine by rational design? Arch Virol. 2021; 166: 27-33.

[112] Van Regenmortel MHV. Development of a preventive HIV vaccine requires solving inverse problems which is unattainable by rational vaccine design. Front Immunol. 2018; 8: 2009.

[113] Van Regenmortel MHV. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites. J Immunol Methods. 1998; 216: 37-48.

[114] Kim M, Sun ZYJ, Rand KD, Shi X, Song L, Cheng Y, et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol. 2011; 18: 1235-43.

[115] Bosshard HR. Molecular recognition by induced fit: how fit is the concept? News Physiol Sci. 2001; 16: 171-3.

[116] Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol. 1994; 4: 857-67.

[117] Kulkarni P, Uversky VN. Intrinsically disordered proteins: the dark horse of the dark proteome. Proteomics. 2018; 18: e1800061.